US FDA shows willingness to be flexible in using foreign device clinical trial data
This article was originally published in SRA
Executive Summary
The Food and Drug Administration's draft guideline on acceptance of medical device clinical trial data from studies conducted outside the US (OUS) is a positive for the industry and shows the US agency's increased willingness to be flexible on this topic, says Amy K Dow from law firm Epstein Becker & Green1-3.